Cermáková et al. reported that zanubrutinib, a second-generation Bruton tyrosine kinase inhibitor approved for relapsed/refractory marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia (WM), counteracts anthracycline resistance by targeting aldo-keto reductase 1C3 (AKR13) and inhibits daunorubicin efflux mediated by ABCB1, ABCC1, and ABCG2, suggesting a possible use in acute myeloid leukemia [122]. The gene discussed is BTK; the disease is marginal zone lymphoma.